Home > Pipeline
Mablink focuses its efforts on cancers with high unmet medical needs and, to demonstrate the high potential of its proprietary PSARlink⢠technology, the first ADCs are addressing molecular targets for which they have already shown clinical promise.
Mablink is currently developing three ADC programs based on a camptothecin derivative (a topoisomerase I inhibitor) as payload:
Discovery
Preclinical
Phase I
Phase II
Disc.
Precl.
Ph. I
Ph. II
Solid Tumors
Multiple Myeloma / Lymphomas
Acute Myeloid Leukemia